Conflict of interest claim hits FDA contract

8 January 2007

A US Food and Drug Administration official allegedly influenced the decision by the agency to terminate a contract for a data project with one supplier and hire, without competitive tendering, a firm for which her husband was a paid advisor. According to the Los Angeles Times newspaper, "the FDA's handling of the matter illustrates how a small but well-positioned contractor gained a foothold - and how conflict of interests restraints are only as strict as the officials who enforce them."

Mark Boster, who recommended the Virginia-based Platinum Solutions to his wife, has since been hired in an executive capacity by the firm. In November 2006, Platinum Solutions won an extension to its $4.0 million contract.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight